EISAI CO. LTD/ JP3160400002 /
| 5/3/2024 8:11:59 AM | Chg. +0.6600 | Volume | Bid7:44:37 PM | Ask7:44:37 PM | Market Capitalization | Dividend Y. | P/E Ratio |
|---|---|---|---|---|---|---|---|
| 39.3600EUR | +1.71% | 0 Turnover: 0.0000 |
38.9900Bid Size: 180 | 40.5500Ask Size: 180 | 11.45 bill.EUR | - | - |
GlobeNewswire
4/29
BeyondSpring Provides Business Update and Reports Year End 2023 Financial Results
GlobeNewswire
3/29
Adlai Nortye Announces Appointment of Dr. Archie Tse as the Head of Research & Development
GlobeNewswire
3/27
Allarity Therapeutics Makes Strategic Pivot to Focus Solely on Accelerating Stenoparib Toward Regula...
GlobeNewswire
3/12
How Do Companies Avert Further Frustration among Neurologists Due to Relyvrio’s (Amylyx) Phase 3 Fai...
GlobeNewswire
3/4
Biogen Highlights New Data at the International Conference on Alzheimer’s and Parkinson’s Diseases (...
GlobeNewswire
2/28
PulseSight Therapeutics Launches to Advance Non-viral Gene Therapies with Disruptive Minimally-Invas...
GlobeNewswire
2/22
Neurologists Report Frustration with Efficacy and Logistical Issues Around Eisai/Biogen’s Leqembi, A...
GlobeNewswire
1/22
PDS Biotech Announces Retirement of Lauren V. Wood, M.D., and Appointment of Kirk V. Shepard, M.D., ...
GlobeNewswire
12/19/2023
Centralized Marketing Authorizations of Generic Versions of TECFIDERA® are Revoked by the European C...
GlobeNewswire
12/7/2023
TScan Therapeutics Appoints R. Keith Woods to its Board of Directors, Bringing Expertise in Commerci...
GlobeNewswire
12/5/2023
Allarity’s Early Phase 2 Stenoparib Data Indicates Clinical Benefit in Women with Advanced Ovarian C...
GlobeNewswire
11/17/2023
Adlai Nortye Announces Completion of Patient Enrollment in Global Phase III Clinical Trial of Buparl...
GlobeNewswire
11/6/2023
Acumen Pharmaceuticals, Inc. and Halozyme Enter Global Collaboration and License Agreement to Develo...
GlobeNewswire
11/2/2023
Ractigen Presents Preclinical Results of Its saRNA Therapeutic Targeting DMD/BMD at the Oligonucleot...
GlobeNewswire
10/30/2023
Abingworth raises $356 million for new Clinical Co-Development Co-Investment Fund (CCD-CIF)
GlobeNewswire
10/25/2023
Eisai Presents New LEQEMBI® (lecanemab-irmb) Investigational Subcutaneous Formulation Interim Study ...
GlobeNewswire
10/23/2023
Elevar Therapeutics Names Brian Cunningham Vice President of Sales and Kenneth Rankin Vice President...
GlobeNewswire
10/23/2023
SEED Therapeutics, a BeyondSpring Subsidiary, Appoints Mr. Ko-Yung Tung to the Board of Directors
GlobeNewswire
10/19/2023
Biogen to Present New Data at the Clinical Trials on Alzheimer’s Disease (CTAD) 2023 Meeting
GlobeNewswire
10/18/2023
X4 Pharmaceuticals Announces Appointment of Industry Veteran R. Keith Woods to Board of Directors
